GEODE CAPITAL MANAGEMENT, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 196 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2018. The put-call ratio across all filers is 0.55 and the average weighting 0.2%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$106,489,828
+8.1%
2,787,349
+2.1%
0.01%
+8.3%
Q2 2023$98,480,801
-2.0%
2,730,268
+3.8%
0.01%
-7.7%
Q1 2023$100,492,709
+70121.1%
2,631,387
+4.6%
0.01%
-35.0%
Q4 2022$143,109
-99.9%
2,515,097
+1.5%
0.02%
+33.3%
Q3 2022$97,935,000
-8.9%
2,476,864
+1.4%
0.02%
-6.2%
Q2 2022$107,478,000
+7.5%
2,442,698
-2.5%
0.02%
+33.3%
Q1 2022$99,960,000
+0.5%
2,506,534
+1.3%
0.01%0.0%
Q4 2021$99,502,000
-0.5%
2,474,566
+0.6%
0.01%
-7.7%
Q3 2021$100,031,000
-10.0%
2,458,973
+0.5%
0.01%
-13.3%
Q2 2021$111,101,000
+17.5%
2,446,622
+7.9%
0.02%
+7.1%
Q1 2021$94,521,000
+4.0%
2,267,258
+6.6%
0.01%
-6.7%
Q4 2020$90,878,000
+69.3%
2,127,800
+4.1%
0.02%
+36.4%
Q3 2020$53,690,000
+4.8%
2,043,024
+6.9%
0.01%0.0%
Q2 2020$51,216,000
+51.2%
1,910,341
+1.4%
0.01%
+22.2%
Q1 2020$33,883,000
-49.3%
1,883,508
-50.0%
0.01%
+28.6%
Q4 2019$66,836,000
+136.2%
3,769,666
+106.6%
0.01%0.0%
Q3 2019$28,297,000
-10.2%
1,824,500
-0.5%
0.01%
-12.5%
Q2 2019$31,505,000
+18.7%
1,833,838
+11.3%
0.01%
+14.3%
Q1 2019$26,538,000
-40.4%
1,648,355
-45.8%
0.01%0.0%
Q4 2018$44,494,000
+69.6%
3,041,314
+110.6%
0.01%0.0%
Q3 2018$26,234,000
+10.8%
1,443,904
+2.9%
0.01%0.0%
Q2 2018$23,675,000
-5.1%
1,403,421
+10.2%
0.01%
-12.5%
Q1 2018$24,958,000
-1.5%
1,274,018
+1.8%
0.01%
-11.1%
Q4 2017$25,348,000
+26.6%
1,251,161
+8.5%
0.01%
+28.6%
Q3 2017$20,028,000
+35.2%
1,153,116
-0.2%
0.01%
+16.7%
Q2 2017$14,816,000
+18.8%
1,155,799
+20.1%
0.01%
+20.0%
Q1 2017$12,473,000
+39.6%
962,500
+6.4%
0.01%
+25.0%
Q4 2016$8,934,000
-12.4%
904,285
+7.1%
0.00%
-20.0%
Q3 2016$10,203,000
+52.3%
844,687
+8.8%
0.01%
+25.0%
Q2 2016$6,698,000
-5.0%
776,138
+4.3%
0.00%0.0%
Q1 2016$7,048,000
-45.6%
744,320
-0.4%
0.00%
-42.9%
Q4 2015$12,952,000
+37.9%
747,424
+6.9%
0.01%
+16.7%
Q3 2015$9,393,000
-38.8%
699,444
+2.8%
0.01%
-33.3%
Q2 2015$15,356,000
+63.5%
680,137
+3.4%
0.01%
+80.0%
Q1 2015$9,391,000
+66.6%
657,669
+12.5%
0.01%
+66.7%
Q4 2014$5,638,000
+5.9%
584,391
-0.1%
0.00%0.0%
Q3 2014$5,324,000
-3.9%
585,204
+4.3%
0.00%
-25.0%
Q2 2014$5,542,000
-20.6%
561,019
+2.1%
0.00%
-20.0%
Q1 2014$6,978,000
-3.7%
549,479
+13.7%
0.01%0.0%
Q4 2013$7,244,000
+60.5%
483,283
+18.3%
0.01%
+25.0%
Q3 2013$4,512,000
+56.8%
408,684
+12.8%
0.00%
+33.3%
Q2 2013$2,877,000362,3030.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2018
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders